Compare Microsoft (MSFT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Natera Inc. Common Stock — how do they compare? Microsoft trades at $531.96 (market cap $4.04T), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Microsoft is far larger — about 70.8× Natera Inc. Common Stock's market cap, and Microsoft pays a 0.72% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Natera Inc. Common Stock for 0 Days on average.
| MSFT | NTRA | |
|---|---|---|
Market Cap | $4.04T | $57.03B |
Volume | 23,799,223 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $543.45 | $425.64 |
52-Week Low | $352.83 | $179.42 |
Typical Hold Time | 142 Days | 0 Days |
Enterprise Value | $4.02T | $56.18B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $543.45, up 0.43% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.74 beating estimates of $4.24, continuing a trend of earnings outperformance. Revenue growth accelerated to $281.72B in 2025 with impressive 40.31% net income margin. Analyst consensus remains overwhelmingly positive with 82% buy ratings and $577.52 price target representing 6.3% upside potential.
Microsoft's AI leadership and cloud dominance position it for sustained growth, though elevated P/E of 30.28 and RSI levels near 83 suggest potential near-term consolidation. Key risks include increased capital expenditure pressures and competitive threats in AI infrastructure. The stock offers strong long-term prospects but may face volatility from valuation concerns and macroeconomic headwinds affecting tech sector performance.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
